Evolus, Inc. (NASDAQ:EOLS) Q2 2019 Earnings Conference Call - Final Transcript

Aug 12, 2019 • 08:00 am ET


Evolus, Inc. (NASDAQ:EOLS) Q2 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good day, ladies and gentlemen, and welcome to the Evolus Q2 Earnings Conference Call. [Operator Instructions]

I would now like to introduce your host for today's conference, Mr. Ashwin Agarwal, Vice President, Finance, Investor Relations and Treasury. Sir, please go ahead.

Ashwin Agarwal

Thank you, operator, and welcome to everyone participating on today's call. This call is also being broadcast live over the Internet at evolus.com and a replay of the call will be available on the Company's website for 30 days. On today's call are David Moatazedi, President and Chief Executive Officer; Lauren Silvernail, Chief Financial Officer and EVP, Corporate Development; Mike Jafar, Chief Marketing Officer; and Rui Avelar, Chief Medical Officer and Head of R&D.

In our remarks today, we will include statements that are considered forward-looking statements within the meaning of United States securities laws. In addition, management may make additional forward-looking statements in response to your questions. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which may affect the Company's business strategy, operations or financial performance.

A detailed discussion of the risks and uncertainties that the Company faces is contained in its annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Actual results may differ materially from those expressed in or implied by the forward-looking statements. The Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

Additionally, the discussion today will include non-GAAP financial measures. These non-GAAP measures should be considered in addition to and not as a substitute for or in isolation from our GAAP results. A reconciliation of GAAP to non-GAAP results may be found in our earnings release, which was furnished with our Form 8-K filed today with the SEC and may also be found on our Investor Relations website at investors.evolus.com.

And now, let me hand the call over to David.

David Moatazedi

Good morning, and thank you all for joining our second quarter 2019 earnings and business update call. Let me start by saying that it's a very exciting time at Evolus. As you may recall from our Investor Day, we outlined three phases to our launch. The first phase was pre-launch, and included a high touch customer engagement strategy to prepare the market, the hiring of a specialized sales force of 140 representatives, and the scientific support from two publications and key medical journals, including the largest aesthetic pivotal head-to-head trial versus the market leader.

On May 15, we entered the second phase of our launch, a 90 day focused effort against a single program named J.E.T. We believe, J.E.T. to be the largest experienced program to hit the U.S. aesthetics market. J.E.T. offers aesthetic providers the opportunity to receive up to three shipments of Jeuveau. Our goal was to rapidly build a large base of experience and confidence in the market to maximize our launch trajectory.

I'm pleased to report, through last week, we have achieved several key highlights. More than 5,000 aesthetic practices are